October 17th 2023
This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Expert Illustrations & Commentaries™: Targeting Immune Cells to Treat Multiple Sclerosis
View More
15th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™
May 11, 2024
View More
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
4th Annual International Congress on the Future of Women’s Health™
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Data aid in treatment for vulvovaginal health, sexual function after cancer
October 11th 2021Analyzing the relationship between data from patient self-reports and clinician ratings of vulvovaginal tissue health following cancer can help provide better sexual function treatment for patients, according to a recent study.
Read More
FDA grants trastuzumab deruxtecan breakthrough therapy designation for breast cancer
October 5th 2021The designation was based on data from the DESTINY-Breast03 phase 3 trial, and this is now the second BTD for trastuzumab deruxtecan in breast cancer, bringing its total number of BTDs to 4, according to an AstraZeneca press release.
Read More
Breast cancer and cervical cancer screenings on the decline
August 2nd 2021According to data from the Centers for Disease Control’s (CDC) National Breast and Cervical Cancer Early Detection Program, the total number of cancer screening tests declined 87% for breast cancer and 84% for cervical cancer during April 2020.
Read More
Highlights from the 2020 San Antonio Breast Cancer Symposium
December 25th 2020Following the 2020 San Antonio Breast Cancer Symposium, Erika P. Hamilton, MD, and William J. Gradishar, MD, shared their key takeaways and insights from the most impactful data presented during this year’s meeting.
Read More
FDA safety alert: Efficacy concerns for a combination therapy in breast cancer treatment
September 16th 2020Officials from the Food and Drug Administration (FDA) issued a safety alert on Sept. 8 about potential efficacy and safety concerns with Tecentriq in combination with Paclitaxel for breast cancer treatment.
Read More
Insulin resistance contributes to racial disparities in breast cancer prognosis in US women
August 4th 2020The lack of data on the possible connection between race and breast cancer prognosis is what led a group of Mount Sinai researchers to conduct this new multicenter, cross-sectional study.
Read More